The complaint, Mazzarino v. ADMA Biologics, Inc., et al. (No. 26-cv-04793), alleges that the company and its executives violated federal securities laws by failing to disclose critical information in offering documents. According to the suit, the firm purportedly utilized channel stuffing to artificially inflate revenue figures and failed to maintain adequate internal controls. These omissions allegedly rendered the company’s public statements regarding its financial operations materially misleading, resulting in investor losses when the details reached the market.
In section Releases
Investors Face August 10 Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit. The litigation, filed in the District of New Jersey, centers on allegations of undisclosed related party transactions and revenue inflation.
Law firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is representing the class. Investors seeking to participate or gather more information may contact Managing Partner Lewis Kahn at 1-833-538-3666 or via the firm’s website. While the August 10 deadline applies to those wishing to serve as a lead plaintiff, the firm notes that investors are not required to hold that role to be eligible for potential recovery.
Comments (0)
No comments yet. Be the first!